CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 69 enrolled
Drug / intervention
neuropsychological testing +1 morebehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02544074
NCT02544074N/ACompleted

Validity of the Electronic Self-Administered Gerocognitive Examination (eSAGE)

Ohio State University·observational·Posted Sep 9, 2015·Updated Mar 25, 2025

In Brief

An observational study evaluating neuropsychological testing and eSAGE testing for Mild Cognitive Impairment and Dementia. Completed, enrolled 69 participants across 1 site.

Detailed Summary

The Self-Administered Gerocognitive Examination (SAGE) is a valid and reliable cognitive assessment tool used to identify both Mild Cognitive Impairment (MCI) and early dementia. SAGE's self-administered feature, pen and paper format, and four equivalent interchangeable forms allows it to be given in almost any setting, does not require any staff time to administer and makes it practical to rapidly screen large numbers of individuals in the community or in their home.This trial is being conducted to study the validity of SAGE in a digital format (eSAGE) for cognitive screening. The investigators will analyze the data to learn the correlations between eSAGE and gold standard neuropsychological testing designed to differentiate normal cognition from MCI and early dementia. The investigators will also find out whether the paper (SAGE) and electronic (eSAGE) versions of SAGE could be used interchangeably or not. Addendum: The eSAGE was previously validated in an earlier stage of this trial. It was initially designed for tablet use and the exact same test has recently been formatted for smartphone use. This addendum is being conducted to study the validity of the smartphone eSAGE compared to the tablet eSAGE for cognitive screening.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsBrain Test, Inc.

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 9, 2015
Enrollment StartJan 1, 2015
Primary CompletionNov 13, 2024
TodayJul 2, 2026
Enrollment to primary: 9.9 yearsPosted 10.8 years ago

Interventions

neuropsychological testingbehavioral

standard neuropsychological testing including brief standardized assessments

eSAGE testingbehavioral

Neuropsychological testing including the eSAGE tablet and eSAGE smartphone